Cryo-Cell International Inc. Common Stock (CCEL)

FairStock Score: 26/100 — RISKY

Key Financials

Strengths

• Generates $159,919 in annual free cash flow (0.5% yield on market cap)
• Strong Piotroski F-Score of 8/9 indicating robust financial health across profitability, leverage, and efficiency metrics
• Attractive 16.3% dividend yield providing steady income returns

Concerns

• Revenue declining at 3.6% year-over-year signals potential demand weakness or market share loss
• Altman Z-Score of -0.6 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

Cryo-Cell International Inc. Common Stock is a micro-cap healthcare company valued at $30 million. The business generates $31 million in annual revenue with a 0.2% net margin and $159,919 in free cash flow. From a quality standpoint, Cryo-Cell shows near-perfect Piotroski F-Score of 8/9 indicating exceptional financial health and distressed Altman Z-Score of -0.6 warrants caution. On valuation, the stock is 1.9% FCF yield. Growth dynamics show revenue growing at -3.6% and profit growth of -83.3%. The 16.3% dividend yield adds an income component for patient holders. Our composite FairStock Score of 26/100 reflects below-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Improving fundamentals and sector tailwinds could drive meaningful earnings growth, compressing the effective multiple for patient investors. With $159,919 in annual free cash flow (0.5% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer